Systemic Sclerosis Dermal Fibroblasts Induce Cutaneous Fibrosis Through LOXL4: New Evidence from 3D Skin-like Tissues.
Systemic sclerosis (SSc) is a clinically heterogeneous disease characterized by increased collagen accumulation and skin stiffness. Our previous work demonstrated that TGF-β induces extracellular matrix (ECM) modifications through lysyl oxidase-like 4 (LOXL4), a collagen cross-linking enzyme, in bioengineered human skin equivalents (hSE) and self-assembled stromal tissues (SAS). The goal of this study was to use hSE and SAS to investigate cutaneous fibrosis and the role of LOXL4 in SSc pathogenesis. SSc-derived dermal fibroblasts (SScDFs, n=8) and normal dermal fibroblasts (NDFs, n=6) were incorporated into hSE and SAS. These 3D skin-like microenvironments were used to study the effect of dysregulated LOXL4 on ECM remodeling, fibroblast activation and response to TGF-β stimulation. SScDFs-SAS showed increased stromal thickness, collagen deposition, and IL-6 secretion compared to NDFs-SAS (P<0.05). In hSE, SScDFs altered collagen as seen by a more mature and aligned fibrillar structure (P<0.05). Both tissue models embedded with SScDFs demonstrated enhanced stromal rigidity with increased collagen crosslinking (P<0.05), upregulation of LOXL4 expression (P<0.01) and innate immune signaling genes. Conversely, knockdown of LOXL4 suppressed rigidity, contraction and αSMA expression in SScDFs-hSE and TGF-β-induced ECM aggregation and collagen crosslinking in SAS. A limitation to the development of effective therapeutics for SSc is the lack of in vitro, human model systems that replicate human skin. Results of this work demonstrate that SAS and hSE serve as complimentary in vitro skin-like models for investigation of the mechanisms and mediators that drive fibrosis in SSc and implicate a pivotal role for LOXL4 in SSc pathogenesis.